Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.

Contreras-Hernández I, Mould-Quevedo JF, Silva A, Salinas-Escudero G, Villasís-Keever MA, Granados-García V, Dávila-Loaiza G, Petersen JA, Garduño-Espinosa J.

Br J Cancer. 2008 Jun 3;98(11):1762-8. doi: 10.1038/sj.bjc.6604367. Epub 2008 May 27.

2.

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.

Paz-Ares L, García del Muro X, Grande E, González P, Brosa M, Díaz S.

Clin Transl Oncol. 2008 Dec;10(12):831-9.

PMID:
19068454
3.

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.

Blanke CD, Huse DM.

J Med Econ. 2010;13(4):681-90. doi: 10.3111/13696998.2010.534670. Epub 2010 Nov 10. Review.

PMID:
21067355
4.
5.
6.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

7.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

8.

The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.

Chabot I, LeLorier J, Blackstein ME.

Eur J Cancer. 2008 May;44(7):972-7. doi: 10.1016/j.ejca.2008.02.041. Epub 2008 Mar 26.

PMID:
18372169
9.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25.

10.

Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G.

Clin Drug Investig. 2007;27(2):85-93.

PMID:
17217313
11.

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.

Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.

J Med Econ. 2013 Sep;16(9):1106-19. doi: 10.3111/13696998.2013.819357. Epub 2013 Jul 19.

PMID:
23808902
12.

[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].

Nishida T, Omori T, Ueshima S.

Gan To Kagaku Ryoho. 2011 May;38(5):733-7. Japanese.

PMID:
21566432
13.

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P.

Ann Oncol. 2012 Jul;23(7):1680-7. doi: 10.1093/annonc/mdr598. Epub 2012 Feb 21.

PMID:
22357255
14.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
15.

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.

Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review.

16.

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.

Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A.

Invest New Drugs. 2010 Dec;28(6):866-75. doi: 10.1007/s10637-009-9306-9.

PMID:
19730791
17.

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

Ruka W, Rutkowski P, Szawłowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W.

Eur J Surg Oncol. 2009 Jan;35(1):87-91. doi: 10.1016/j.ejso.2008.01.003. Epub 2008 Mar 4.

PMID:
18289826
18.

[Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].

Ishikawa T, Kanda T, Kosugi S, Yajima K, Hatakeyama K.

Gan To Kagaku Ryoho. 2011 Jun;38(6):916-21. Japanese.

PMID:
21677482
19.

Advances in the treatment of gastrointestinal stromal tumours.

Judson I, Demetri G.

Ann Oncol. 2007 Sep;18 Suppl 10:x20-4. Review.

PMID:
17761719
20.

Second line therapies for the treatment of gastrointestinal stromal tumor.

Joensuu H.

Curr Opin Oncol. 2007 Jul;19(4):353-8. Review.

PMID:
17545799

Supplemental Content

Support Center